Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy

Journal of Immunology

Volumn 165, Issue 12, 2000, Pages 7240-7245

  Williams, R O ^a   Marinova Mutafchieva, L ^a   Feldmann, M ^a   Maini, R N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COLLAGEN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LYMPHOCYTE ANTIBODY; SERUM AMYLOID P; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE EROSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; MALE; MOUSE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034671575     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.12.7240     Document Type: Article

References (35)

1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α
2. Repeated therapy with a monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis
3. Treatment with a chimaeric monoclonal antibody to tumour necrosis factor a suppresses disease activity in rheumatoid arthritis results of a multi-centre, randomised, double blind trial
4. The therapeutic effects of an engineered human anti-tumour necrosis factor α antibody (CDP571) in rheumatoid arthritis
5. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
6. Inhibitory effect of TNFα antibodies on synovial cell interleulkin-1 production in rheumatoid arthritis
7. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
8. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
9. Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
10. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
11. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4
12. Transgenic mice expressing human tumour necrosis factor, a predictive genetic model of arthritis
13. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
14. Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response
15. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
16. Anticytokine treatment of established type II collagen-reduced arthritis in DBA/1 mice a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra
17. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis comparison of efficacy animal models with human clinical data
18. Different roles of tumour necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis
19. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
20. Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin
21. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis
22. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen induced arthritis
23. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors
24. Control of established experimental allergic encephalomyelitis by inhibition of tumour necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins
25. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody
26. Interleukin 1 receptor blockade attenuates the host inflammatory response
27. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG
28. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
29. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction
30. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA)
31. Quantitation of serum amyloid P component by an enzyme-linked immunoassay
32. The acute phase response
33. Murine type II collagen arthritis association of an acute-phase response with clinical course
34. The major acute phase reactants C-reactive protein, serum amylold P component and serum amylold A protein
35. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen- and zymosan-induced arthritis